In addition to their direct anti-tumor effect, new targeted drugs (i.e. BTK inhibitors, PI3K inhibitors, and the Bcl-2 inhibitor venetoclax) have demonstrated the ability to modulate non-neoplastic immune cell populations. The gene discussed is BTK; the disease is neoplasm.